STERNA BIOLOGICALS TO ATTEND INTERNATIONAL PARTNERING AND INVESTOR CONFERENCES IN NOVEMBER

Marburg, Germany, November 07, 2019 - Sterna biologicals GmbH & Co. KG ("sterna"), an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases, today announced that the Company will participate and present at the following partnering and investor conferences in November:

- ^{2019 - 25th Annual International Partnering Conference taking place from November 11 to 13, 2019 in Hamburg, Germany}

- (EKF, German Equity Forum) - Europe's largest independent capital markets meeting held from November 25 to 27, 2019 in Frankfurt, Germany
Presentation Venture Stage on Tuesday, Nov 26, 2 pm

"Sterna is in the midst of an exciting time: Over the past months, we have kicked off our phase 2b development program for our first-in-class DNAzyme hgd40 in moderate to severe asthma and ulcerative colitis. This brings us closer to our ultimate goal of bringing novel break-through therapies to patients who are in desperate need of well tolerated, more effective treatment options for their moderate to severe type 2 inflammatory diseases," said Christian Pangratz, CEO and Managing Director of sterna. "At the upcoming conferences, we look forward to updating potential partners and investors about our development milestones that we have achieved since we announced our phase 2a successes."

Christian Pangratz will be available for one-on-one meetings with interested parties over the course of both conferences.

Parties interested in meeting with sterna biologicals at BIO-Europe^(R) 2019 are requested to send an invitation through the event's ^{system, those who wish to meet with the Company at EKF are asked to contact sterna at . The Company will also be available for media interviews and background discussions.}

 

ABOUT STERNA BIOLOGICALS

Sterna biologicals GmbH & Co. KG is an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases such as asthma, chronic obstructive pulmonary disease (COPD), atopic dermatitis, and ulcerative colitis. By targeting transcription factors that play a central role in regulating Th1- and Th2-driven inflammatory mechanisms, the Company's proprietary DNAzyme-based drug candidates can intervene with upstream inflammatory processes to address related diseases more effectively. Sterna currently has four programs in Phase 2 development.

For more information, please visit .

 

ABOUT BIO-EUROPE^(R)

BIO-Europe is the preeminent partnering conference of the European life science industry, bringing together international decision makers from the biotechnology, pharmaceutical and financial sectors, offering networking opportunities and private one-to-one meetings. The BIO-Europe 2019 partnering event is expected to draw over 4,000 industry attendees for three days of high-level networking, representing upwards of 2,000 companies from over 60 countries. To learn more about the conference, please visit .

 

ABOUT DEUTSCHES EIGENKAPITALFORUM (EKF)

Deutsches Eigenkapitalforum, which is organized by the Deutsche Boerse, is Europe's largest independent capital markets meeting, which this year is reporting record figures with more than 250 registered companies and an expected 4,000 one-to-one meetings. As a matching platform, the forum connects capital-seeking German and international companies from all industry sectors with institutional investors and analysts .

CONTACT

Christian Pangratz
Chief Executive Officer
sterna biologicals GmbH & Co. KG
Bismarckstrasse 7
35037 Marburg

Tel.: +49 (0)6421.98 30 05 0

For media inquiries:

Anne Hennecke
MC Services AG

Tel.: +49 (0)211.52 92 52 22